Skip to main content
MedPathMedPath Home
Clinical Trials/ACTRN12612000052831
ACTRN12612000052831
Recruiting
未知

Can early response measurement by FDG PET/CT in patients with metastatic colorectal cancer receiving third-line therapy with cetuximab predict the progression-free survival and overall survival?

Chang Gung Memorial Hospital0 sites30 target enrollmentJanuary 11, 2012
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit
ConditionsMetastatic colorectal cancer receiving third-line therapy with cetuximabCancer - Bowel - Back passage (rectum) or large bowel (colon)

Overview

Phase
未知
Intervention
Not specified
Conditions
Metastatic colorectal cancer receiving third-line therapy with cetuximab
Sponsor
Chang Gung Memorial Hospital
Enrollment
30
Status
Recruiting
Last Updated
6 years ago
OverviewInvestigatorsEligibility CriteriaOutcomesSimilar Trials

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
January 11, 2012
End Date
TBD
Last Updated
6 years ago
Study Type
Observational
Sex
All

Investigators

Sponsor
Chang Gung Memorial Hospital

Eligibility Criteria

Inclusion Criteria

  • •1\. at least one measurable lesion as defined by RECIST criteria.
  • •2\. received both the irinotecan\-based and oxaliplatin\-based regimens.
  • •3\. must have tumor specimen determined to have wild\-type K\-ras.

Exclusion Criteria

  • •1\. History of another primary malignancy less than 3 years
  • •2\. Prior treatment with cetuximab or panitumumab

Outcomes

Primary Outcomes

Not specified

Similar Trials

Completed
Not Applicable
Early response evaluation with 18F-FDG PET/CT and immunological profiling of circulating immune cells and tumor-draining lymph nodes in non-small cell lung cancer patients treated with immunotherapy.
NL-OMON48669Antoni van Leeuwenhoek Ziekenhuis50
Recruiting
Not Applicable
Interim FDG PET-CT in Melanoma Metastatic Patient's Treated by Anti-PD1 TherapyMetastatic Melanoma
NCT03888950Centre Hospitalier Universitaire de Nice20
Recruiting
Phase 2
Phase II study of interim FDG-PET-guided response-adapted therapy in pediatric patients with Hodgkin's lymphoma (HL-14)s lymphomaHodgkin&#39
JPRN-UMIN000019093Japanese Pediatric Leukemia/Lymphoma Study Group (JPLSG)50
Active, not recruiting
Phase 2
Phase II study of interim FDG-PET-guided response-adapted therapy in pediatric patients with Hodgkin's lymphoma (HL-14)
JPRN-jRCTs041180174Koga Yuhki50
Recruiting
Not Applicable
The predictive value of FDG-PET-CT early during (chemo-)radiotherapy for local control of advanced stage head and neck cancer
NL-OMON32415Vrije Universiteit Medisch Centrum20